

ENZALUTAMIDE-INDUCED HEART FAILURE WITH REDUCED EJECTION FRACTION

*Mirjana Todorović-Mitić¹, Marija Todorović-Marković², Ana Cvetanović^{1,3},
Milan Čevrljaković¹, Ljubomir Dinić^{4,5}*

Prostate cancer is the second most common malignancy in men and the second leading cause of cancer death. Patients unfit for surgery, with locally advanced or metastatic disease, require androgen-deprivation therapy.

In the past decade, enzalutamide and abiraterone were established in prostate cancer treatment. Their safety profile and clinical evidence showed a significant possibility of cardiovascular complications. Heart failure is more common in patients treated with abiraterone. We report a case of a patient with heart failure induced by enzalutamide. In the review of the literature, enzalutamide-induced heart failure was encountered in only two cases.

Further research on the influence of novel anti-androgen therapy on the cardiovascular system, personalized evaluation of the cardiovascular system, and risk stratification for potential cardiovascular adverse events before initiating therapy are needed.

Acta Medica Medianae 2025;64(3): 118–123.

Key words: *enzalutamide, heart failure, prostate cancer*